Showing 2664 results
- Statement /
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- Statement /
Media Library /
Media Library /
Media Library /- Statement /
Story /Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
- Statement /
- Statement /